Sinopharm develops a stronger booster against Omicron
Chinese firm’s protein-based vaccine elicits a stronger antibody response, study finds
07 January 2022 - 13:02 Roxanne Liu and Ryan Woo
Picture: BLOOMBERG.
Beijing — A protein-based Covid-19 vaccine made by Sinopharm, when given as a booster after two doses of an earlier shot from the Chinese firm, elicited a stronger antibody response against the Omicron variant than a third dose of the original, a study showed.
The study, which was published on Tuesday and had not been peer reviewed, came amid concerns over the effectiveness of Sinopharm’s BBIBP-CorV shot, one of the two leading Covid-19 vaccines exported by China, against the Omicron variant.
An earlier study showed a BBIBP-CorV booster had weaker neutralisation against Omicron than against an older coronavirus strain from the Chinese city of Wuhan.
Sinopharm’s NVSI-06-07 protein-based vaccine, approved for emergency use as a booster in the United Arab Emirates in December, adopts a different technology from the BBIBP-CorV shot, which contains an inactivated form of the coronavirus.
Among 192 healthy adults vaccinated with two BBIBP-CorV doses for six months or longer, the neutralising antibody level against Omicron in those later given an NVSI-06-07 booster was “significantly higher” than that in those who received a BBIBP-CorV third dose, researchers said in a paper.
The antibody-based results are different from the efficacy readings about how well the NVSI-06-07 booster after BBIBP-CorV vaccination would protect people from Omicron-caused disease.
The authors of the paper, including researchers from Sinopharm’s units and Sheikh Khalifa Medical City in Abu Dhabi, cautioned that it remained unclear for how long the NVSI-06-07 booster’s effect would last.
Sinopharm develops a stronger booster against Omicron
Chinese firm’s protein-based vaccine elicits a stronger antibody response, study finds
Beijing — A protein-based Covid-19 vaccine made by Sinopharm, when given as a booster after two doses of an earlier shot from the Chinese firm, elicited a stronger antibody response against the Omicron variant than a third dose of the original, a study showed.
The study, which was published on Tuesday and had not been peer reviewed, came amid concerns over the effectiveness of Sinopharm’s BBIBP-CorV shot, one of the two leading Covid-19 vaccines exported by China, against the Omicron variant.
An earlier study showed a BBIBP-CorV booster had weaker neutralisation against Omicron than against an older coronavirus strain from the Chinese city of Wuhan.
Sinopharm’s NVSI-06-07 protein-based vaccine, approved for emergency use as a booster in the United Arab Emirates in December, adopts a different technology from the BBIBP-CorV shot, which contains an inactivated form of the coronavirus.
Among 192 healthy adults vaccinated with two BBIBP-CorV doses for six months or longer, the neutralising antibody level against Omicron in those later given an NVSI-06-07 booster was “significantly higher” than that in those who received a BBIBP-CorV third dose, researchers said in a paper.
The antibody-based results are different from the efficacy readings about how well the NVSI-06-07 booster after BBIBP-CorV vaccination would protect people from Omicron-caused disease.
The authors of the paper, including researchers from Sinopharm’s units and Sheikh Khalifa Medical City in Abu Dhabi, cautioned that it remained unclear for how long the NVSI-06-07 booster’s effect would last.
Reuters
Germany set to tighten up in the face of Covid surge
CDC cuts Pfizer booster interval to five months
Ireland scraps Covid-19 tests for vaccinated arrivals
Boris Johnson lashes anti-vaxxers for spreading ‘mumbo jumbo’
Would you like to comment on this article?
Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most read
Related Articles
The gold medal bout: Beijing Winter Games bubble vs Omicron
Germany set to tighten up in the face of Covid surge
Fourth Covid-19 vaccine dose lifts antibodies five-fold, Israel says
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.